Abstract. Graves disease (GD) is an autoimmune disorder with genetic predisposition. The polymorphisms 47A→G (Arg16Gly) and 79C→G (Gln27Glu) of the adrenergic ß-2 receptor (ADRB2) gene in the 5q32 region affect the functional reaction to adrenergic stimulation, which contributes to the regulation of immunological response. The -367T→C polymorphism within the 5'-leading regulatory sequence affects ADRB2 transcriptional activity. The aim of the present study was to investigate whether ADRB2 gene variants are associated with susceptibility to GD. All polymorphisms were studied in Polish GD patients (n=300) and healthy control subjects without a family history of autoimmune disorders (n=301). Genotypes were determined by the MassARRAY™ system (Sequenom, San Diego, CA). Gly16 and Gln27 allele frequencies were 61.4% and 55.2% among healthy controls, almost the same as previously reported in 4441 white participants of a cardiovascular health study. We found a higher risk of GD in Gln27 carriers (CC or CG genotypes) than in Glu27 homozygous (GG genotype) participants (OR=1.99, 95% CI: 1.27-3.12, p=0.003, p_corr=0.03). The frequency of the 79GG protective genotype was significantly smaller in the GD patients without symptoms of Graves ophthalmopathy compared to controls (10% vs 22%, OR=0.41, 95% CI: 0.234-0.706, p=0.0017, p_corr=0.015). We didn't find any association of -367T→C or 47A→G genotypes/alleles with Graves disease, however, haplotype analysis has shown a significant difference in haplotype distribution between patients and controls (34% vs 25%, p=0.00073, p_corr=0.0044). In conclusion, Gln27 carriers (79CC or 79GC genotypes) have increased risk of Graves disease. Our results suggest that ADRB2 plays a role in susceptibility to Graves disease in humans.

Introduction
Graves disease (GD) is an autoimmune disorder with inflammatory cytokine imbalance and varying degrees of hyperthyroidism and ophthalmopathy (Graves ophthalmopathy, GO). GD is considered to be a complex trait to which genetic, environmental, and demographic factors contribute interactively (1). Recent genome-wide searches have provided evidence for linkage to loci on multiple chromosomes, however the significance of a particular locus has rarely been confirmed in more than one population (2). Association studies have shown that major histocompatibility complex (MHC) alleles (3), the cytotoxic T lymphocyte antigen-4 (CTLA-4) gene (4-6) and the lymphoid tyrosine phosphatase (PTPN22/LYP) gene (7) confer risk for GD. Products from all of those genes are potentially involved in antigen presentation and T cell recognition. The list of additional candidate genes comprises thyrotropin receptor (TSHR), CD40, interferon-α (IFN-α), tumor necrosis factor-α (TNF-α) and interleukin (IL)-13, but their contribution to the susceptibility to GD awaits confirmation.

The adrenergic ß-2 receptor (ADRB2) is a G protein-coupled receptor that mediates the actions of catecholamines in multiple tissues (8). ADRB2 located on T helper 1 (Th1) cells is an important immunoregulatory factor which upon activation decreases the level of Th1-specific cytokines such as IFN-γ, IL-12, TNF-α and IL-18, which leads to the over-
representation of Th1 cytokines such as IL-4 and IL-13 and the
dominance of humoral immune activity (9). In thyroid
autoimmunity, a mixed Th1 and Th2 pattern has been found
in GD tissue samples, however some studies have shown a
Th1 response in Hashimoto thyroiditis and Th2 response in
GD (10-13). It was recently reported that both the population
of Th1 cells and the ratio of Th1/Th2 cells were lower in GD
and higher in GO as compared to those in controls (14). In
the same study the authors found a positive correlation of
Th1 cell percentage and Th1/Th2 cell ratio with clinical activity
score (CAS) in GO (14). Thus, the adrenergic ß-2 receptor
acting as selective suppressor of Th1-cellular immunity axis
may be a potential candidate contributing to the development
of GD and/or GO. Of note, the ADRB2 gene is located in the
5q32-3 region linked to GD in three linkage studies (15-17).

Several single nucleotide polymorphisms (SNP) have
been detected within the ADRB2 gene intronless sequence
and its 5' upstream regulatory region. In particular, a few of
them present both evidence of functional relevance and a high
degree of heterozygosity, which are the basis for a possible
pathophysiological role in the modulation of 'complex' traits.
The 47A→G (Arg16Gly, dbSNP125: rs17859732) and the
79C→G (Gln27Glu, dbSNP125: rs17859733) polymorphisms
influence a rate of agonist-induced receptor down-regulation
(18-20). The haplotype within the 5' upstream regulatory
region comprising the -367T→C (dbSNP125: rs11959427)
polyorphism impacts promoter activity and transcription rate
(21,22).

The ADRB2 gene SNPs have been reported to be associated
with susceptibility to some inflammatory disorders such as
asthma (23,24) and cardiovascular diseases such as coronary
heart disease (25), congestive heart failure (26,27) and hyper-
tension in diabetics (28). No data concerning ADRB2 gene
association with Graves disease have been reported.

The aim of the present study was to investigate whether
polymorphisms of the ADRB2 gene are associated with the
development of GD and/or GO.

Materials and methods

Subjects. We studied a total of 300 Polish patients (237 females
and 63 males, aged 6-78 years old, mean age 41.1±15.3 years)
with Graves disease diagnosed based on the presence of
hyperthyroidism, diffuse goiter, detectable thyroid-stimulating
hormone receptor autoantibodies (TRAK Lumitest, BRAHMS
Diagnostica, Germany) and/or increased radiiodine uptake, as
described previously (29). Thyroid-associated ophthalmopathy
(GO) was classified according to the clinical activity score
system recommended by the American Thyroid Association
(ATA) Committee (30). Of the GD patients, 108 (82 females
and 26 males, mean age 45.1±14.3 years) showed ophthalmo-
pathy defined as ATA class III or greater and were classified
as GO(+). One hundred and ninety-two patients showed no
ophthalmopathy (ATA class 0), signs of ophthalmopathy
without symptoms (ATA class I), or only soft tissue involve-
ment (ATA class II). The control group comprised 301 healthy
unrelated Polish individuals (206 females and 95 males; aged
15-82 years; mean age 39.3±13.6 years) with no family history
of autoimmune diseases. All study participants were white
and of Polish origin. The research program was approved by
the local ethics committee, and all subjects provided written
informed consent for genetic studies.

Genotyping. Genomic DNA was extracted from peripheral
blood using standard techniques. All SNPs were defined by
PCR and MassARRAY™ system (Sequenom, San Diego,
CA). PCR was performed using 2 ng genomic DNA in 5 μl
reaction with a mixture containing 1X dilution of 10X PCR
buffer (Applied Biosystems, Foster City, CA), 200 nmol of
each primer, 0.4 mmol dATP, dGTP, dTTP, dCTP, and 0.5 U
of AmpliTaq Gold DNA polymerase (Applied Biosystems)
under the following conditions: 94°C for 15 min, followed
by 45 cycles at 95°C for 20 sec, 56°C for 30 sec, 72°C for 1 min,
and a final extension step 72°C for 3 min. MassARRAY
Homogenous MassEXTEND™ (hME) assay (Sequenom)
was conducted according to the manufacturer's instructions.
The primer sequences are available upon request.

Statistical analysis. Statistical analysis was conducted using
R software (http://cran.r-project.org) with additional packages
‘survival’ and ‘genetics’. The Chi-square test was applied
to check the homogeneity in genotype frequency distributions
between the patient group and controls. If any of the expected
counts was <5, the Fisher's exact test was applied. p values
were corrected by multiplying by the number of alleles,
genotypes or haplotypes tested (Bonferroni correction). A
corrected p value (p_corrected) of <0.05 was considered statistically
significant. Genotype frequencies in all groups were checked
for Hardy-Weinberg equilibrium using the Chi-square test.
Cox proportional hazard regression model was applied
to estimate any association between the GD age of onset
and the genotypes. ANOVA analysis was used to compare
differences in age of disease onset between patient sub-
groups. Odds ratios were calculated by Woolf's method. The
population haplotype frequency distribution was estimated
from population genotype data by PHASE version 2.02
software (31,32). The differences in estimated haplotype
frequencies were analyzed by a case-control permutation test
with 1000 iterations implemented in the PHASE software
package. Linkage disequilibrium (LD) was estimated for all
possible SNP pairs using two-side LD parameters: D, D' and
r2. The LD coefficient D represents the difference between
the observed frequency of a two-locus haplotype and the
frequency it would be expected to show if the alleles were
segregating at random. The D' parameter is calculated by
dividing D by its maximum possible value given the allele
frequencies it would be expected to show if the alleles were
segregating at random. The D' parameter is calculated by
dividing D by its maximum possible value given the allele
frequencies at the two loci. A D' value of 1 or -1 indicates
that two SNPs are in complete LD. Power calculation was
performed using PAWE software (http://linkage.rockefeller.
edu/pawe (33,34).

Results

Association of ADRB2 gene polymorphisms with Graves
disease. The genotype distributions of all SNPs for both
groups (cases and controls) were consistent with the Hardy-
Weinberg equilibrium. Genotype frequencies for ADRB2
gene polymorphisms are summarized in Table I. Allele
frequencies for ADRB2 gene polymorphisms are summarized
in Table II.
We found a higher risk of GD in Glu27 carriers (CC or CG genotypes) than in Glu27 homozygous (GG genotype) participants (OR=1.99, 95% CI: 1.27-3.12, p=0.003, pcorr=0.03). The 79C allele frequency appeared to be greater in the GD patients compared to the controls, but this difference was not significant (62% vs 55%; OR=1.32, 95% CI: 1.05-1.79, p=0.024, pcorr=0.14, power 69%).

We didn’t find any association of -367T→C or 47A→G genotypes/alleles with Graves disease (power <57%).

There were six haplotypes of ADRB2 gene polymorphisms in the present study (Table III). Haplotype analysis showed a significant difference in haplotype frequency distribution between patients and controls (the global p=0.001) with increased -367T/47A/79C haplotype frequency in GD patients compared to controls (34% vs 25%, OR=1.55, 95% CI: 1.208-1.999, p=0.00073, pcorr=0.0044).

The linkage disequilibrium (LD) among ADRB2 gene SNPs in GD is summarized in Table IV. We found marked LD

---

Table I. Genotype frequencies of the ADRB2 gene polymorphisms in healthy subjects and patients with Graves disease with or without ophthalmopathy.

<table>
<thead>
<tr>
<th></th>
<th>Healthy subjects n=301</th>
<th>GD total n=300</th>
<th>Ophthalmopathy ATA class 0-II n=192</th>
<th>Ophthalmopathy ATA class III-VI n=108</th>
</tr>
</thead>
<tbody>
<tr>
<td>-367T→C</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT</td>
<td>98 (0.33)</td>
<td>99 (0.42)</td>
<td>59 (0.40)</td>
<td>40 (0.47)</td>
</tr>
<tr>
<td>CT</td>
<td>128 (0.46)</td>
<td>103 (0.44)</td>
<td>69 (0.46)</td>
<td>34 (0.40)</td>
</tr>
<tr>
<td>CC</td>
<td>51 (0.18)</td>
<td>32 (0.14)</td>
<td>21 (0.14)</td>
<td>11 (0.13)</td>
</tr>
<tr>
<td>47A→G</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>39 (0.14)</td>
<td>49 (0.17)</td>
<td>29 (0.16)</td>
<td>20 (0.19)</td>
</tr>
<tr>
<td>AG</td>
<td>139 (0.49)</td>
<td>144 (0.50)</td>
<td>92 (0.51)</td>
<td>52 (0.49)</td>
</tr>
<tr>
<td>GG</td>
<td>103 (0.37)</td>
<td>93 (0.33)</td>
<td>59 (0.33)</td>
<td>34 (0.32)</td>
</tr>
<tr>
<td>79C→G</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>91 (0.32)</td>
<td>105 (0.36)</td>
<td>66 (0.36)</td>
<td>39 (0.37)</td>
</tr>
<tr>
<td>CG</td>
<td>128 (0.46)</td>
<td>148 (0.51)</td>
<td>99 (0.54)</td>
<td>49 (0.47)</td>
</tr>
<tr>
<td>GG</td>
<td>62 (0.22)</td>
<td>36 (0.12)</td>
<td>19 (0.10)</td>
<td>17 (0.16)</td>
</tr>
</tbody>
</table>

a Chi-square test, GG vs CC+GC, x²=8.57, df=1, p=0.0034, pcorr=0.030. b Chi-square test, GG vs CC+GC, x²=9.85, df=1, p=0.0017, pcorr=0.015.

GD, Graves disease; ATA, American Thyroid Association. Values in parentheses represent proportion of individuals expressed as a percentage.

Table II. Allelic frequencies of the ADRB2 gene polymorphisms in healthy subjects and patients with Graves disease with or without ophthalmopathy.

<table>
<thead>
<tr>
<th></th>
<th>Healthy subjects n=301</th>
<th>GD total n=300</th>
<th>Ophthalmopathy ATA class 0-II n=192</th>
<th>Ophthalmopathy ATA class III-VI n=108</th>
</tr>
</thead>
<tbody>
<tr>
<td>-367T→C</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T allele</td>
<td>324 (0.58)</td>
<td>301 (0.64)</td>
<td>187 (0.63)</td>
<td>114 (0.67)</td>
</tr>
<tr>
<td>C allele</td>
<td>230 (0.42)</td>
<td>167 (0.36)</td>
<td>111 (0.37)</td>
<td>56 (0.33)</td>
</tr>
<tr>
<td>47A→G</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A allele</td>
<td>217 (0.39)</td>
<td>242 (0.42)</td>
<td>150 (0.42)</td>
<td>92 (0.43)</td>
</tr>
<tr>
<td>G allele</td>
<td>345 (0.61)</td>
<td>330 (0.58)</td>
<td>210 (0.58)</td>
<td>120 (0.57)</td>
</tr>
<tr>
<td>79C→G</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C allele</td>
<td>310 (0.55)</td>
<td>358 (0.62)</td>
<td>231 (0.63)</td>
<td>127 (0.60)</td>
</tr>
<tr>
<td>G allele</td>
<td>252 (0.45)</td>
<td>220 (0.38)</td>
<td>137 (0.37)</td>
<td>83 (0.40)</td>
</tr>
</tbody>
</table>

a Chi-square test, x²=12.12, df=1, p=0.024, pcorr=0.14, power 69%. b Chi-square test, x²=4.99, df=1, p=0.026, pcorr=0.16, power 71%.

GD, Graves disease; ATA, American Thyroid Association. Values in parentheses represent proportion of individuals expressed as a percentage.
The evidence for genetic involvement in the pathogenesis of GD disease comes from the study of twins, in addition to the observation of familial clustering of the disease. In the study of 8966 Danish twin pairs Brix et al. found a crude concordance rate of 35% for MZ pairs and 3% for DZ pairs, and estimated that 79% of the liability to the development of GD is attributable to genetic factors (35). Although several susceptibility loci were noted in a linkage analysis performed in multiplex families, the results from only three of them were replicated (chromosomes 5, 8 and 20) and only one replication (5q31) was convincing (36). Sakai et al. in a genome-wide analysis performed on 123 GD and/or Hashimoto affected Japanese sib-pairs (15) found significant linkage for microsatellite marker D5S436 in the region 5q31 (LOD=3.14). This result was replicated in 54 Chinese multiplex GD pedigrees with a maximum two-point LOD score of 2.8 for D5S436, and an LOD score of 4.31 for D5S2090, another marker in this region (16). Akamizu et al. performed an association study in 440 Japanese GD patients and 218 controls and confirmed a significant association between GD and two more markers in the 5q31-33 region (17). The ADRB2 gene is located 3 Mb downstream from marker D5S436 and 1 Mb downstream from marker D5S2090.

The sympathetic nervous system via ß-2-adrenergic receptors causes selective suppression of the Th1-cellular immunity axis and a shift toward Th2-mediated humoral immunity (9,37). It might be of great importance in GD since this disorder is characterized by an abnormality in immune regulation.

The present report is the first clinical study on the significance of the functional polymorphisms of the ADRB2 gene in Graves disease. We have demonstrated that the Gln27 carriers (CC or GC genotypes) are at a higher risk of GD than Glu27 homozygous participants. Studies of the effects of ADRB2 gene polymorphisms on its product function showed enhanced agonist-induced receptor desensitization (in vitro) in the 16Gly variant and resistance to desensitization in the 27Glu variant as compared to wild-type alleles (16Arg and Gln27, respectively (18,19). For that reason, our findings may lead to the conclusion that the ADRB2 receptor variant characterized by increased agonist-mediated down-regulation is responsive for susceptibility to GD, but a single SNP result should be considered in terms of larger haplotype, as it is possible that another SNP, linked to Gln27Glu, is of superior functional importance. The Arg16Gly polymorphism, in

Table III. Estimated frequencies of the ADRB2 gene haplotypes in healthy subjects and patients with Graves disease.

<table>
<thead>
<tr>
<th>Haplotypes (positions -367/47/79)</th>
<th>Healthy subjects</th>
<th>Gravesh disease</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Frequency</td>
<td>Standard error</td>
</tr>
<tr>
<td>1 TAC</td>
<td>0.244</td>
<td>0.010</td>
</tr>
<tr>
<td>2 CGG</td>
<td>0.228</td>
<td>0.008</td>
</tr>
<tr>
<td>3 CGC</td>
<td>0.189</td>
<td>0.008</td>
</tr>
<tr>
<td>4 TAG</td>
<td>0.143</td>
<td>0.009</td>
</tr>
<tr>
<td>5 TGC</td>
<td>0.121</td>
<td>0.008</td>
</tr>
<tr>
<td>6 TGG</td>
<td>0.073</td>
<td>0.008</td>
</tr>
</tbody>
</table>

The differences in estimated haplotype frequencies were analyzed by a case-control permutation test with 1000 iterations implemented in the PHASE software package; the global p=0.001. *Chi-square test, \( \chi^2=11.41, df=1, p=0.00073, p_{corr}=0.0044 \).

Table IV. The linkage disequilibrium (LD) among ADRB2 gene polymorphisms in patients with Graves disease.

<table>
<thead>
<tr>
<th>-367T&gt;C</th>
<th>47A&gt;G</th>
<th>79G&gt;C</th>
</tr>
</thead>
<tbody>
<tr>
<td>-367T&gt;C</td>
<td>D'=0.97</td>
<td>D'=0.67</td>
</tr>
<tr>
<td>47A&gt;G</td>
<td>r²=0.62</td>
<td>r²=0.64</td>
</tr>
<tr>
<td>79G&gt;C</td>
<td>r²=0.64</td>
<td>r²=0.41</td>
</tr>
</tbody>
</table>

Association between the ADRB2 gene polymorphisms and Graves ophthalmopathy. The frequency of the 79GG protective genotype was significantly smaller in the GD patients without GO (ATA class ≤ II, n=192) compared to the controls (10% vs 22%, OR=0.41, 95% CI: 0.234-0.706, p=0.0017, \( p_{corr}=0.015 \); Table I). The 79G allele frequency appeared to be smaller in the GD patients without GO compared to the controls, but this difference was not significant (37% vs 45%; OR=0.73, 95% CI: 0.558-0.955, p=0.026, \( p_{corr}=0.16, power 71\%; Table II) .

Age of onset. The mean age of GD onset was 37 years for females and 42 years for males; this difference was significant (p=0.015). The results of the Cox proportional hazards regression indicated no association between age of GD onset and any genotype (p=0.3). Patients with ophthalmopathy (ATA ≥ III) were significantly older (mean 41 years) than cases without evident eye symptoms (ATA ≤ II, mean 36 years) with p=0.002. There was no difference in age of GO onset between genders (p=0.11).

Discussion

The evidence for genetic involvement in the pathogenesis of GD disease comes from the study of twins, in addition to the observation of familial clustering of the disease. In the study
strong linkage disequilibrium with Gln27Glu, seems to play the dominant role, since the 16Gly phenotype was observed regardless of whether the position 27 amino acid was Gly or Gln (38). We performed the haplotype analysis and found the -367T/47A/79C haplotype to be substantially more prevalent in GD patients than in controls and thus conferring a higher risk of GD. This haplotype appears to be resistant to agonist-induced receptor desensitization (proved for 47A/79C diplo-
type) in addition to having a higher ‘baseline’ expression level (proved for -367T, which always goes with 47A/79C) and therefore appears to represent the highly functional ADRB2 receptor variant. However, this function of the entire -367T/47A/79C haplotype needs to be confirmed experimentally (discussed further in ref. 39).

The role of ADRB2 gene polymorphisms as disease risk factors has been demonstrated in asthma (23, 24), coronary heart disease (25), congestive heart failure (26, 27), hypertension in diabetes (28) and recently in sudden cardiac death (40). Interestingly, the 47A/79C diplo-
type (Arg16/Gln27) was reported to be associated with an elevated total IgE level in pollen allergy (41). The increased level of IgE is also observed in GD patients. Of note, cigarette smoking, a known environmental factor involved in the development of autoimmune diseases, has a similar to 47A/79C diplo-
type impact on the sympathetic outflow, i.e. it increases adrenergic action (42).

We speculate that the highly functional ADRB2 receptor variant confers an increased risk for GD by more efficiently polarizing the immune response towards antibody production. Additional studies must be conducted to clarify whether the differences in GD risk are related to the changes in immune response described for the -367T/47A/79C haplotype, and whether the haplotype is a marker for other determinants of GD risk. Also the final tissue- and time-dependent impact of this haplotype on receptor function is yet to be evaluated (43). We didn’t find any direct association of either the Arg16Gly or the -167T–C polymorphism with susceptibility to GD, probably because our study was under-powered to full address this. Since we observed the Gly16 and Gln27 allele frequencies among healthy controls to be 61.4% and 55.2%, respectively, almost the same as previously reported in 4441 white participants of a cardiovascular health study (40), we report that the control group data was correct.

Acknowledgments

We thank Dr Albert de la Chapelle for advice and support. This work was supported by the Polish State Committee for Scientific Research (grant no. 3PO3B15525). Magdalena Stepnoska was supported by a Ph.D. fellowship from the University of Gdansk, Poland.

References